---
title: "Maze Therapeutics, Inc. (MAZE.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/MAZE.US.md"
symbol: "MAZE.US"
name: "Maze Therapeutics, Inc."
industry: "Pharmaceuticals"
datetime: "2026-03-03T13:18:48.297Z"
locales:
  - [en](https://longbridge.com/en/quote/MAZE.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/MAZE.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/MAZE.US.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/MAZE.US.md) | [繁體中文](https://longbridge.com/zh-HK/quote/MAZE.US.md)


# Maze Therapeutics, Inc. (MAZE.US)

## Company Overview

Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, which is in phase I clinical trial for the treatment of chronic kidney disease. The company also offers MZE001, a clinical program for the treatment of Pompe disease. Maze Therapeutics, Inc.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [www.mazetx.com](https://www.mazetx.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-03-03T04:30:14.000Z

**Overall: D (0.71)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 128 / 188 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -100.00% |  |
| Net Profit YoY | -455.45% |  |
| P/B Ratio | 5.78 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 2194727840.84 |  |
| Revenue | 0.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -213.81% | E |
| Profit Margin | 0.00% | D |
| Gross Margin | 0.00% | E |
| Revenue YoY | -100.00% | E |
| Net Profit YoY | -455.45% | E |
| Total Assets YoY | 119.27% | A |
| Net Assets YoY | 281.84% | A |
| Cash Flow Margin | 0.00% | D |
| OCF YoY | -100.00% | E |
| Turnover | 0.00 | E |
| Gearing Ratio | 10.10% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Maze Therapeutics, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-100.00%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-455.45%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "5.78",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "2194727840.84",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "0.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-213.81%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "0.00%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "-100.00%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-455.45%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "119.27%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "281.84%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "-100.00%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.00",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "10.10%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -21.63 | 205/188 | 207.52 | 160.53 | 119.88 |
| PB | 5.78 | 148/188 | 5.29 | 4.25 | 2.14 |
| PS (TTM) | 530.95 | - | 530.95 | 254.16 | 2.94 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Eli Lilly (LLY.US) | A | A | B | E | B | B |
| 02 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | C | B |
| 03 | Roche (RHHBY.US) | A | B | B | D | C | B |
| 04 | NOVARTIS AG (NVS.US) | A | B | C | D | C | B |
| 05 | AstraZeneca (AZN.US) | A | B | C | D | C | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-24T05:00:00.000Z

Total Analysts: **10**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 9 | 90% |
| Overweight | 1 | 10% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 45.61 |
| Highest Target | 60.00 |
| Lowest Target | 43.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/MAZE.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/MAZE.US/norm.md)
- [Related News](https://longbridge.com/en/quote/MAZE.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/MAZE.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**